Safety and Effectiveness of a Fixed-Dose Combination of Cephalexin Extended Release and Clavulanate Potassium in Bacterial Sore Throat and Uncomplicated Skin and Soft-Tissue Infections: A Multicentre, Open-Label, Phase IV Study in India
This study was prospectively registered on Clinical Trials Registry, India [CTRI/2022/07/044190] on 20 July, 2022; URL: https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NzA4MTA=&Enc=&userName= .
Authors
- Sumit Agarwal (ORCID: https://orcid.org/0000-0002-2552-6784)
- Dipak D. Patil (ORCID: https://orcid.org/0000-0002-4826-4537)
- Sadhna Joglekar (ORCID: https://orcid.org/0000-0001-5739-4942)
- Harshal Chaudhari (ORCID: https://orcid.org/0000-0001-5542-7544)
- Lalit Lakhwani
- Suyog Mehta (ORCID: https://orcid.org/0000-0001-7553-4128)
- S Chavan
- Mandodari Rajurkar (ORCID: https://orcid.org/0000-0002-5513-0545)
- Dipak M. Solanki
- Sapan Behera
- Sunil Panda
- Parth Bipinkumar
- Neha Sharma
- Supriya Sonowal
- Pravin Ghadge
Institutions
- Grant Medical College and Sir Jamshedjee Jeejeebhoy Group of Hospitals (IN)
- CARE Hospitals (IN)
- Midas Multispeciality Hospital (IN)
- Oyster & Pearl Hospital (IN)
- Sparsh Hospital (IN)
- Sun Pharma (India) (IN)
- Sun Pharma Advanced Research (India) (IN)
- M. P. Shah Medical College (IN)
- B.J. Medical College (IN)
Publication Details
- Journal
- Drugs - Real World Outcomes
- Published
- 2026-01-23
- DOI
- https://doi.org/10.1007/s40801-025-00533-7
- Primary Topic
- Antimicrobial Resistance in Staphylococcus
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sun Pharma